Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

December-12-01

New Drug May Be Effective in Treating Breast Cancer

Studies presented at the San Antonio Breast Cancer Symposium indicate that a new class of hormone therapy may replace Tamoxifen in the treatment of certain types of breast cancers. In post-menopausal women with locally advanced or metastatic breast cancer and also in post-menopausal women with estrogen-receptor and HER-2 positive breast cancer, data suggests that Femara, a drug developed by the Swiss Pharmaceutical company Novartis, is more effective than the commonly used Tamoxifen in shrinking tumor growth. More importantly, in randomized-double blind studies, paid for in part by Novartis, Femara offered a better survival advantage than Tamoxifen. Side effects are essentially the same for both drugs. Femara is an aromatase inhibitor, a drug that prevents the hormone androgen from being converted to estrogen. Tamoxifen is an anti-estrogen, a drug that blocks the effects of already-existing estrogen from exerting its effects at the cellular level.

Research indicates that all breast cancer is not created equal. Future treatment plans will become more and more individually tailored as scientific advancements reveal more about the particulars of certain types of breast cancer. Therefore, it is critical that basic research and clinical trials continue in order to provide maximal therapeutic options for all women.

The Feminist Majority Foundation has launched an emergency campaign for mifepristone (also known as RU-486 and the abortion pill), an important anti-progesterone drug that blocks the effects of progesterone, at the cellular level. Preliminary studies indicate that mifepristone may be effective in treating certain types of breast cancer. Much basic research and clinical trials have come to a standstill however because anti-abortion forces have made it extremely difficult for scientists to even procure the drug to explore its exciting non-abortion medical potential.

Media Resources: Novartis; Associated Press, 12/11/01; Feminist Majority Foundation


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

4/22/2014 US Ranks 16th in 2014 Social Progress Index - The Social Progress Imperative recently released its 2014 Social Progress Index, ranking the United States in 16th place among 132 countries. Harvard Business School Professor Michael Porter, a Republican who led the report team, told CNN's Fareed Zakaria that he was surprised by the ranking. . . .
 
4/22/2014 Florida Supreme Court Recognizes Anti-Discrimination Protections for Pregnant Workers - The Florida State Supreme Court ruled last week that pregnancy discrimination is a form of sex discrimination under Florida employment law. The 6-1 decision allows Peguy Delva to proceed with her lawsuit against her employer, real estate developer Continental Group. . . .
 
4/21/2014 Arizona Governor Signs Bill Allowing Suprise Inspections of Abortion Clinics - Arizona Governor Jan Brewer signed a bill into law last week allowing state health authorities to conduct surprise inspections of abortion clinics without a warrant. HB 2284 repeals an Arizona law that requires a judge to give approval for inspections of abortion clinics. . . .